Pierre Foidart

Also affiliated with Harvard University, University of Liège, Dana-Farber Cancer Institute, Centre Hospitalier Universitaire de Liège, Dana-Farber Brigham Cancer Center

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers”.

BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers

Science Translational Medicine(2020)10.1126/scitranslmed.aax2625

N/A

0.751DataRank · unranked

148 citations

Rania El Botty, Sophie Château‐Joubert, Ahmed Dahmani, Élodie Montaudon, Sophie Leboucher +29 more

ZBTB7A is a modulator of KDM5-driven transcriptional networks in basal breast cancer

Cell Reports(2024)10.1016/j.celrep.2024.114991

N/A

0.362DataRank · unranked

9 citations

Marco Seehawer, Zheqi Li, Andriana Patmanidis, Triet M. Bui, Pierre Foidart +19 more

Midkine as a driver of age-related changes and increase in mammary tumorigenesis

Cancer Cell(2024)10.1016/j.ccell.2024.09.002

N/A

0DataRank · unranked

41 citations

Ernesto Rojas Jiménez, Zheqi Li, Triet M. Bui, Marco Seehawer, Jun Nishida +8 more